Market Place
Sourcing Support
Novartis` Biologic Beovu ( Brolucizumab) Receives Approval in the U.S.
19 Dec 2022 //
FDA
Novartis Korea`s AMD treatment Beovu wins expanded indication
17 Aug 2022 //
KOREABIOMED
Novartis Pharms` Biologic Beovu (Brolucizumab) Receives Approval in the U.S.
18 Feb 2022 //
FDA
Health Canada Issues Recall of Novartis Pharmaceuticals Canada`s BEOVU (brolucizumab)eutica
05 Feb 2022 //
HEALTH CANADA
Novartis reports positive data from diabetic macular oedema trial of Beovu
10 Dec 2021 //
CLINICALTRIALSARENA
Beovu shows positive results in two-year Phase III trial
10 Dec 2021 //
EUROPEANPHARMACEUTICALREVIEW
Novartis announces positive results from Phase III trial of Beovu
09 Dec 2021 //
PHARMAFILE
US FDA & EMA accepts Novartis’ sBLA for Beovu to treat diabetic macular edema
14 Oct 2021 //
PHARMABIZ
Novartis announces positive phase III results of Beovu in diabetic macular edema
18 Aug 2021 //
PHARMABIZ
Novartis announces positive results from PhIII trials of Beovu
17 Aug 2021 //
PRESS RELEASE
Novartis stops three late-stage studies of Beovu eye drug citing patient safety
03 Jun 2021 //
PHARMAPHORUM
Novartis stops three late-stage studies of Beovu eye drug citing patient safety
01 Jun 2021 //
FIRSTWORLDPHARMA
Novartis`s Beovu® receives positive recommendation from CADTH & CDEC
06 Oct 2020 //
YAHOO
Novartis reported positive topline results in a Phase III for its Eylea
15 Sep 2020 //
ENDPOINTS
European Medicines Agency (EMA) approves safety label update for Novartis Beovu
14 Sep 2020 //
PRESS RELEASE
Novartis`s Beovu (brolucizumab-dbll) Receives Supplemental Approval in US
16 Jun 2020 //
FDA
US FDA approves updated Novartis Beovu® label, to include additional safety
10 Jun 2020 //
NOVARTIS
Boehringer Ingelheim sharpens retinal strategy, scooping up dry AMD drug
13 May 2020 //
ENDPTS
Safety woes won`t hurt Beovu`s blockbuster potential: Novartis
28 Apr 2020 //
FIERCE PHARMA
Eye drug side effects are real, Novartis confirms in new warning
10 Apr 2020 //
BIOPHARMADIVE
`Lightning struck`: Safety alert hurt docs` views of Beovu
04 Mar 2020 //
FIERCE PHARMA
Novartis` hot new eye drug Beovu tied to potential vision loss
24 Feb 2020 //
FIERCE PHARMA
Beovu bags EU approval in wet AMD
18 Feb 2020 //
PHARMATIMES
Regeneron builds preventive case for Eylea with 2-year data
11 Feb 2020 //
FIERCE PHARMA
Regeneron builds preventive case for Eylea with 2-year data
11 Feb 2020 //
FIERCE PHARMA
Five meds recommended in final 2019 CHMP meeting
16 Dec 2019 //
PHARMA TIMES
EMA’s Meeting highlights from CHMP) recommended five medicines for approval
14 Dec 2019 //
EMA
Novartis hopes for 25 more blockbuster nods in the coming years
05 Dec 2019 //
FIERCE PHARMA
Regeneron touts Eylea countermeasures as Novartis goes aggressive with Beovu launch
06 Nov 2019 //
FIERCE PHARMA
Regeneron defends bid to challenge Merck in lung cancer
05 Nov 2019 //
BIOPHARMADIVE
Novartis Beovu (Brolucizumab-dbII) Receives Approval In US
08 Oct 2019 //
FDA
Novartis` brolucizumab tees up battle against Eylea, Lucentis
17 Apr 2019 //
FIERCE PHARMA
Novartis announces FDA filing acceptance and Priority Review of (RTH258)
16 Apr 2019 //
PR NEWSWIRE
Novartis announces FDA filing acceptance, Priority Review of brolucizumab
15 Apr 2019 //
PR NEWSWIRE
